The British-Swedish pharma major certainly has a strong competitive edge for BTC treatment in the country
36.4% of patients with diabetic neuropathic pain in 2021 were completely treatment refractory and would benefit from new treatment options.
Results showed a statistically significant and clinically meaningful improvement in investigator-assessed progression-free survival
Pluvicto and Scemblix launches are progressing well and we are awaiting data in earlier lines of therapy.
Transformation to pure-play Innovative Medicines company nears completion
The WAVEsystem with the WAVEcontrol 4.0 embedded
Condon joins DTx Pharma with more than 20 years of experience in business development, commercial planning, and operations.
Viralex (Inosine Pranobex) is an immunomodulatory agent with broad-spectrum antiviral properties
The DalPhos ligands were developed by Prof. Mark Stradiotto and his research team at the Department of Chemistry, Dalhousie University
Subscribe To Our Newsletter & Stay Updated
_256_275.jpeg)
